Haemacure gets Hemaseel trial approval:
This article was originally published in Clinica
Haemacure has been given approval by the FDA to begin a Phase II trial of its Hemaseel biological tissue glue. The adhesive is a liquid derived from human plasma which is a capable of stopping bleeding. The company, based in Montreal, Canada, intends to demonstrate the efficacy of its glue to control post-surgical bleeding and will begin the trial in the US later this month. US company ClinTrials Research is managing the study.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.